华北制药获得注射用盐酸万古霉素药品注册证书

Core Viewpoint - The company has received the drug registration certificate for injectable vancomycin hydrochloride (0.5g) from the National Medical Products Administration, indicating that the product meets the basic requirements for centralized procurement bidding and has therapeutic effects equivalent to the original product [1] Group 1 - The approval of injectable vancomycin hydrochloride (0.5g) enhances the company's product portfolio in the anti-infection field [1] - The new product complements the existing product, vancomycin (injection of vancomycin hydrochloride), thereby improving the company's offerings in the market [1]